Welcome, Guest. Please login or register.
March 28, 2024, 03:46:07 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 772946
  • Total Topics: 66310
  • Online Today: 424
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 0
Guests: 381
Total: 381

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Zinc Finger Proteins Put Personalized HIV Therapy Within Reach  (Read 360046 times)

0 Members and 1 Guest are viewing this topic.

Offline Cosmicdancer

  • Member
  • Posts: 199
Re: Zinc Finger Proteins Put Personalized HIV Therapy Within Reach
« Reply #500 on: February 26, 2015, 10:19:34 am »
Sangamo BioSciences Presents New Clinical Data at CROI 2015 From Trial of ZFP Therapeutic® Designed to Provide Functional Control of HIV

Data Demonstrate Cytoxan Preconditioning Combined with CD4/CD8 ZFN-modified T-cell Product Reduces Viral Load to Limit of Quantification in One Subject of Three; Delays Onset of Viremia in Another Subject

Company Also Announces FDA Acceptance of IND Application for New HIV/AIDS Clinical Trial Using ZFN-modification of Hematopoietic Stem Cells
RICHMOND, Calif., Feb. 26, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new clinical data from its Phase 1/2 clinical trial (SB-728-1101). The study is designed to evaluate SB-728-T, a ZFP Therapeutic® generated by ZFN-mediated genome editing of T-cells to knockout the CCR5 gene, which encodes a critical co-receptor for HIV infection. SB-728-T is being developed as a potential 'functional cure' for HIV/AIDS. The data were presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) which is being held in Seattle from February 23 to 26, 2015.

"In our studies of SB-728-T, we have observed remarkable effects on both the viral load and the levels of the viral reservoir," said Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "Data and models developed by other groups have defined the characteristics of so-called 'elite controllers' whose immune systems prevent their HIV infections from progressing to AIDS, without antiretroviral drugs (ART). As part of the 1101 study, we are evaluating whether an improvement in HIV control can be obtained by including CD8 T-cells in our SB-728-T product, mimicking a phenotype observed in 'elite controllers.'  The data demonstrate that we can generate a CD4/CD8 SB-728-T cell product that can be successfully combined with Cytoxan preconditioning to drive robust engraftment. Moreover, in the three subjects treated we have already observed encouraging increases in total CD8 T-cells and effects on the viral load during a treatment interruption (TI)."

The 1101 study was designed to evaluate the effect of increasing doses of Cytoxan® preconditioning as a method to maximize engraftment of ZFN- modified cells (SB-728-T) in which both copies of the CCR5 gene had been disrupted, making the cells fully resistant to HIV infection.  Data from Cohorts 1-5 of the 1101 study (18 subjects) demonstrated a dose-related increase in both total CD4 T-cell and ZFN modified CD4 T-cell engraftment in response to Cytoxan preconditioning up to 1.0 g/m2. In addition, all subjects underwent a TI and were taken off ART at sixteen weeks post infusion. Four subjects from Cohort 1-5 remain on long-term TI and have remained off ART for at least 40 weeks.

You can read the full press release here.

http://investor.sangamo.com/releasedetail.cfm?ReleaseID=898529
Summer, 2007 - &$#@?
November, 2007 - Tested poz, 300,000 vl, 560 cd4
Feb, 2008 - 57,000 vl, 520 cd4, started Atripla
2/2008 - 5/2015 - undetectable on Atripla
May, 2015 - UD, switched to Complera
September, 2015 - UD, 980 cd4, switched to Stribild (Complera interacted with acid reflux medication)
January, 2016 - Stribild, UD, 950 cd4
June, 2016 - UD, 929 cd4

 


Terms of Membership for these forums
 

© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.